|
Papillary thyroid carcinoma
|
0.900 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
MGD |
|
|
|
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
(iii) BRAF positivity correlates with the presence of ETE in PTC, but this relationship is lost within classical/tall cell PTC if follicular variants are excluded from the analysis.
|
20860430 |
2010 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
38.2% of human PTCs displayed high expression of AXL that positively correlated with RAI-refractoriness and disease persistence or recurrence, especially when combined with v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation.
|
31181609 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
54.5% and 27.6% of Thy5 and Thy4, respectively, were BRAF-mutated, against 12.1% of follicular lesions and 9.3% of follicular lesion with atypia (Thy3).
|
20950194 |
2010 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
58% PTCs presented a genetic alteration either RET/PTC rearrangement, BRAF V599E mutation or both: three cases of PTCs (25%) presented a RET/PTC rearrangement; three cases of PTCs (25%) presented a BRAF V599E mutation and in one case (8%) both alterations were identified.
|
15859312 |
2005 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
80 (60.61%) of papillary thyroid carcinomas exhibited BRAF(V600E) mutation in a range of 7.7% to 46.3% of the total BRAF alleles.
|
25400776 |
2014 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
99 PTC and 11 nodular hyperplasia FFPE thyroid tissues are evaluated for the BRAF V600E mutation by the Idylla tests and compared with peptide nucleic acid-clamping PCR, real-time PCR and pyrosequencing.
|
27543599 |
2017 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
: The detection of free circulating mutant BRAF in patients with PTC is possible and future studies are warranted to determine its clinical significance.
|
19626635 |
2010 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
PTC with RET/PTC rearrangement as well as the TPC-1 cell line (the only one harboring RET/PTC rearrangement) did not show the BRAF(V599E) mutation.
|
12881714 |
2003 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid carcinomas are associated with nonoverlapping activating mutations of RET, NTRK, RAS and BRAF, which altogether are present in approximately 70% of cases.
|
16551863 |
2006 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid carcinomas (PTCs) commonly have BRAF(V600E) mutation.
|
17387744 |
2007 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid carcinomas (PTC) are the most common type of thyroid malignancy with one of the two mutations, RET/PTC rearrangement or BRAF mutation.
|
18676765 |
2008 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
PTC cases were also examined for their BRAF(V600E) mutational status.
|
21730105 |
2011 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that generate RET/PTC and TRK oncogenes and with BRAF-V600E and RAS gene mutations.
|
23132790 |
2013 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid carcinoma samples with BRAF V600E mutation were shown to have higher glucose transporter 1, hexokinase II, carbonic anhydrase IX, and tumoral monocarbonylate transporter 4 expression levels.
|
28347233 |
2017 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
PTC status, measures of aggressiveness (e.g. tumor size) and BRAF V600E mutation were included as outcomes.
|
28772138 |
2017 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
PTC with BRAF mutation presents a histology of conventional PTC, and follows an aggressive clinical course.
|
30788603 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
PTC with BRAF V600E mutation showed higher expression of ATX, LPA1, LPA2, and LPA3 than PTC without BRAF V600E mutation (p < 0.001).
|
31455351 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V599E) mutations were unique to PTCs, and not found in any of the other types of differentiated follicular neoplasms arising from the same cell type (0 of 46).
|
12670889 |
2003 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation occurred in PTC at a significantly higher frequency in male patients than in female patients.
|
12907632 |
2003 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas.
|
15095090 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation occurs later in thyroid tumor progression and is restricted mainly to PTC and anaplastic thyroid carcinoma.
|
15980887 |
2005 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation was found by MASA in 19/43 (44.2%) of PTC, including 14/31 (45.2%) classic forms and 5/12 (41.7%) follicular variants.
|
16452550 |
2006 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
B-RAF (V600E) was significantly associated with the classic variant of PTC (P = 0.0001) and with an older age at diagnosis (P = 0.01).
|
16728573 |
2006 |